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IMPORTANCE Individuals can be classified as being at clinical high risk (CHR) for psychosis if
theymeet at least one of the ultra–high-risk (UHR) inclusion criteria (brief limited intermittent
psychotic symptoms [BLIPS] and/or attenuated psychotic symptoms [APS] and/or genetic
risk and deterioration syndrome [GRD]) and/or basic symptoms [BS]. Themeta-analytical risk
of psychosis of these different subgroups is still unknown.
OBJECTIVE To compare the risk of psychosis in CHR individuals whomet at least one of the
major inclusion criteria and in individuals not at CHR for psychosis (CHR−).
DATA SOURCES Electronic databases (Web of Science, MEDLINE, Scopus) were searched until
June 18, 2015, along with investigation of citations of previous publications and amanual
search of the reference lists of retrieved articles.
STUDY SELECTION We included original follow-up studies of CHR individuals who reported
the risk of psychosis classified according to the presence of any BLIPS, APS and GRD, APS
alone, GRD alone, BS, and CHR−.
DATA EXTRACTION AND SYNTHESIS Independent extraction bymultiple observers and
random-effects meta-analysis of proportions. Moderators were tested with meta-regression
analyses (Bonferroni corrected). Heterogeneity was assessed with the I2 index. Sensitivity
analyses tested robustness of results. Publication biases were assessed with funnel plots and
the Egger test.
MAIN OUTCOMES ANDMEASURES The proportion of each subgroupwith any psychotic
disorder at 6, 12, 24, 36, and 48 or moremonths of follow-up.
RESULTS Thirty-three independent studies comprising up to 4227 individualswere included. The
meta-analytical proportion of individualsmeeting eachUHR subgroup at intakewas: 0.85APS
(95%CI, 0.79-0.90), 0.1 BLIPS (95%CI, 0.06-0.14), and0.05GRD (95%CI, 0.03-0.07). There
were no significant differences in psychosis risk at any time point between theAPS andGRDand
theAPS-alone subgroups. Therewas a higher risk of psychosis in the any BLIPS greater thanAPS
greater thanGRD-alone subgroups at 24, 36, and48ormoremonths of follow-up. Therewas no
evidence that theGRD subgroup has a higher risk of psychosis than the CHR− subgroup. There
were too fewBS or BS andUHR studies to allow robust conclusions.
CONCLUSIONS AND RELEVANCE There is meta-analytical evidence that BLIPS represents
separate risk subgroup compared with the APS. The GRD subgroup is infrequent and not
associated with an increased risk of psychosis. Future studies are advised to stratify their
findings across these different subgroups. The CHR guidelines should be updated to reflect
these differences.
JAMA Psychiatry. 2016;73(2):113-120. doi:10.1001/jamapsychiatry.2015.2324
Published online December 30, 2015.
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T he first clinical service for individuals potentially pro-dromal for psychosis (Personal Assessment and CrisisEvaluation Clinic) was set up in 1995 by Yung et al1 in
Melbourne,Australia, on thebasis of theultra–high-risk (UHR)
criteria. Inclusion required the presence of one ormore of the
following: attenuated psychotic symptoms (APS), brief lim-
ited intermittent psychotic symptoms (BLIPS), and/or ge-
netic risk and deterioration (GRD) criteria (for historical de-
tails, see thearticlebyFusar-Poli et al2). These subgroupswere
defined apriori as independent entry criteria, and they are in-
dependently operationalized on the psychometric assess-
ment tools that are used to ascertain the UHR state. Adoles-
cents and young adults at increased risk of developing
psychotic disorders can thus be identified using standard-
izedpsychometric instrumentswith consistent reliability and
goodpredictive value.3 The risk of psychosis inUHR individu-
als peaksduring theensuing2years.4However, despite agreat
deal of research for reliable clinical, behavioral, or neurobio-
logicalmeasures that canpredict the subsequent onset of psy-
chosis, researchers have yet to discover such a holy grail.5
The lack of reliable and valid predictive biomarkers6 may
reflect a number of factors, including the declining transition
risks in recent years,7,8 small sample sizes, a lack of external
validation,6 and methodologic pitfalls.9 However, a key
potential confounder is that the UHR category may itself be
heterogeneous.10 When the UHR paradigm was devised, the
founders suggested that there may be different UHR sub-
groups, each associated with different levels of risk. In par-
ticular, it was hypothesized that the group with the presence
of any BLIPS (ie, BLIPS alone, BLIPS and APS, or BLIPS and
APS and GRD) would have the highest level of risk, followed
by the group with APS and GRD (additive clinical and genetic
effect on psychosis risk), the group with APS alone, and then
the GRD-alone group.11 However, to our knowledge, this
assumption has not previously been systematically tested
using a meta-analytical approach. A further complication is
that a comparably high risk of psychosis has been indepen-
dently associated with the basic symptoms (BS) criteria,12
which are thought to represent another separate and different
subgroup, featuring an earlier phase of prodromal psychosis
than the UHR criteria.2 Many high-risk centers now include
individuals with UHR and/or BS in their studies, and this com-
bination can be termed as defining a clinical high-risk (CHR)
state for psychosis. The extent to which all these different
subgroups can be considered as belonging to a single CHR
group is unclear. However, if the CHR category is heteroge-
neous, this may hamper ongoing efforts to understand the
mechanisms underlying the risk of psychosis and the devel-
opment of preventive treatments.
In the present study, we investigated this issue by con-
ducting, to our knowledge, the first robustmeta-analytical in-
vestigation of risk stratification across different CHR sub-
groups.We test thehypothesis of heterogeneous risk levels in
UHR, stratifiedas anyBLIPSgreater thanAPSandGRD,greater
than APS, alone greater than GRD alone.11 To test the actual
risk of psychosis, these subgroups are additionally compared
with individuals assessed for suspicion of psychosis risk but
not meeting CHR criteria (hereafter CHR−). This analysis is
complemented by meta-regressions, investigating the effect
ofpotential confounderson themeta-analytical estimates, and
by secondary analyses on BS subgroups.
Methods
Search Strategy
Two investigators (M.C., G.R.) conducted 2-step literature
searches. First, theWebofKnowledgedatabasewas searched,
incorporating both the Web of Science and MEDLINE. The
search was extended until June 18, 2015, including abstracts
in theEnglish languageonly. Theelectronic researchused sev-
eral combinations of the following keywords: at risk mental
state,psychosis risk,prodrome,prodromal psychosis,ultrahigh
risk, high risk, help seeking patients, psychosis prediction, psy-
chosis onset, and thenamesof thediverseCHRassessment in-
struments. Second, Scopus was used to investigate citations
of possible previous reviews andmeta-analyses on transition
topsychosis inCHR individuals andamanual searchof the ref-
erence lists of retrieved articles. Articles identified through
these 2 steps were then screened in relation to the selection
criteria on the basis of reading their abstracts. Discrepancies
were discussed with another author (P.F.-P.) and resolved
through consensus. The articles surviving this selectionwere
assessed for eligibility on thebasis of full-text reading, follow-
ing the Meta-Analyses and Systematic Reviews of Observa-
tionalStudies (MOOSE)checklist (eTable1 in theSupplement).13
Selection Criteria
Studies were eligible for inclusion when the following criteria
were fulfilled: (1) an original article, written in English;
(2) inclusion of CHR individuals, defined according to estab-
lished international UHR criteria (ie, Comprehensive Assess-
ment of at Risk Mental States, Structured Interview for
Psychosis–Risk Syndromes, Basel Screening Instrument for
Psychosis) and/or BS criteria (Schizophrenia Proneness Instru-
ments, Bonn Scale for the Assessment of Basic Symptoms)
instruments14-19 or CHR− individuals; (3) prospective assess-
ment of risk of psychosis onset with at least one follow-up
time point (6, 12, 24, 36, and/or ≥48months); (4) reported risk
of psychosis stratified across the following CHR subgroups:
any BLIPS, APS and GRD, APS alone, GRD alone (individuals
meeting multiple UHR criteria were stratified for symptom
severity as previously suggested: any BLIPS greater than APS
and GRD, greater than APS alone, greater than GRD alone11),
BS, and/or across the CHR− subgroup. CHR− individuals were
defined as help-seeking individuals referred to ultra-high-risk
services (UHR) and/or to expert clinicians (BS) for suspicion of
psychosis risk and assessedwith the standardized CHR instru-
ments but not meeting CHR criteria. This comparison group
was thus drawn from the same pool of referrals that provided
the individuals whomet the CHR criteria.
Whenstudieshadnot already subdivided theCHRsample
and assessed risk of psychosis in each subgroup, the corre-
sponding author was contacted and invited to use the origi-
nal raw data to stratify the samples. A similar approach was
adoptedwith respect to collectionof potentialmoderators for
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each subgroup. Exclusion criteriawere (1) abstracts, pilot data
sets, and articles in languages other than English; (2) articles
that did not use internationally validated definitions for CHR
(ie,UHRand/orBS); (3) articleswithoverlappingdata sets; and
(4) studies that could not provide data on transition risk in re-
lation to these subgroups. In the case of multiple publica-
tions deriving from the same study population, we selected
the articles that reported the longest follow-up data set. The
literature search was summarized according to the Preferred
Reporting Items for Systematic Reviews and Meta-analyses
(PRISMA) guidelines.20
Recorded Variables
Data extractionwas independently performedby 2 investiga-
tors (M.C., G.R.). To estimate the primary outcome variable,
we extracted the baseline sample size and the number of in-
dividuals with psychosis at each follow-up time point across
each UHR subgroup. To estimate the secondary outcome, we
further collected number of transitions across the UHR only,
BS only, and BS and UHR subgroups. Additional moderators
tested inmeta-regression analyses are listed in the statistical
analysis below. Quality assessment is described in the
eMethods in the Supplement.
Statistical Analysis
The primary outcome was the risk of psychosis onset in CHR
individuals, stratified according to the initial UHR subgroups,
with the followingorder: anyBLIPS greater thanAPSandGRD,
greater than APS alone, greater than GRD alone, greater than
CHR−. This was calculated as the proportion of baseline indi-
viduals across each subgroup with any psychotic diagnosis at
6, 12, 24, 36, and48ormoremonthsof follow-up.Thebaseline
sample size was conservatively used to avoid a bias toward
overly high transition risks at longer follow-ups resulting from
an increase of dropouts over time. In case of a lack of meta-
analyticaldifferencesbetween theAPSaloneandAPSandGRD
subgroups, it was planned a priori to repeat the analyses with
these2subgroupscombined ina singlegroup (ie,BLIPSgreater
than APS, greater than GRD, greater than CHR−11). The meta-
analysiswasconductedwith themetaproppackage21 of STATA
statisticalsoftware,version13.1 (StataCorp),whichhasbeenspe-
cifically developed for pooling proportions in a meta-analysis
ofmultiple studies. The 95%CIswere based on score (Wilson)
procedures.22 Because proportions were often expected to be
small,weusedFreeman-TukeyDoubleArcsinetransformation23
to stabilize the variances and then perform a random-effects
meta-analysis implementing theDerSimonian-Lairdmethod.24
The influenceofmoderatorswas testedusingmeta-regression
analyseswith themetareg function,25 and themetaregpermu-
tation test optionwas used to estimate the 95%CIs. The slope
of themeta-regression line (β-coefficient: direct or inverse) in-
dicates the strength of an association betweenmoderator and
outcome. The meta-regressions were conducted when at
least 10 studies were available for eachmoderator26 and were
Bonferronicorrectedformultiple testing.Heterogeneityamong
studypoint estimateswas assessedusingQ statistics. Thepro-
portion of the total variability in the effect size estimates was
evaluated with the I2 index,27 which does not depend on the
number of studies included. Because meta-analyses of obser-
vational studies are expected to be characterized by signifi-
cant heterogeneity, random-effects models were used. In ad-
dition, we conducted sensitivity analyses to investigate the
influence of each single study on the overall risk estimate by
omitting one study at a time, using Stata’s user-written func-
tionmetainf.28,29Astudywasconsidered tobe influential if the
pooledmean estimatewithout it was not within the 95%CI of
the overall mean. Publication biases were assessed with the
metafunnel functionofStata thatproduced funnelplots for as-
sessing small-study reportingbias inmeta-analysis30 andwith
the Egger test31 in metabias32 function of Stata. We investi-
gated as secondaryoutcomes the risk of psychosis in individu-
als whomet the original UHR criteria only, in individuals who
met the BS criteria only, and in individuals who met both the
BS and UHR criteria.
Results
Database
The literature search (Figure 1) identified 33 independent ar-
ticles,mostofwhichcontributedmore thanoneUHRorBSsub-
group.Thedetails of the includedstudies and typesof samples
provided are detailed in eTable 2 in the Supplement. The age
and sex of the CHR samples, psychometric CHR instruments,
diagnostic instrument used to assign the psychotic diagno-
sis, duration of follow-up, and exposure to antipsychotics at
baseline and baseline to follow-up, quality assessment, and
baseline sample sizes of the CHR and CHR− patient sub-
groups are detailed in eTable 2 in the Supplement.
The overall characteristics of the UHR samples are de-
tailedintheeResults intheSupplement.Acrossthestudiesusing
the UHR criteria (n = 3624), the baseline meta-analytical pro-
portionof individualsmeeting the 3 subgroupswas as follows:
Figure 1. Preferred Reporting Items for Systematic Reviews
andMeta-analyses (PRISMA) Diagram
1896 Abstracts identified 
through database searching 
(Web of Knowledge)
92 Abstracts identified 
through manual search
1468 Abstracts after 
duplicates removed
860 Abstracts screened
113 Full-text articles (PDFs) 
assessed for eligibility
33 Studies included in the 
meta-analysis
747 Abstracts excluded 
on initial review
80 Full-text articles (PDFs)
excluded
32
44
4
No data available
Overlapping data set
No clinical high-risk 
sample
27 Authors contacted who 
provided additional data
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APS, 0.85 (95% CI, 0.79-0.90); BLIPS, 0.10 (95% CI, 0.06-
0.14); and GRD, 0.05 (95%CI, 0.03-0.07) (eFigure 1A, B, and C
in the Supplement) (individuals who met multiple intake cri-
teria were categorized as planned: BLIPS greater than APS,
greater than GRD11).
Meta-analytical Stratification of Individuals
at Ultra–High-Risk for Psychosis
There were no significant meta-analytical differences be-
tween the APS and GRD and the APS-alone subgroups at any
time point (Figure 2). We therefore combined these 2 sub-
groups into a single APS subgroup and contrasted it with the
BLIPSandGRDsubgroups (BLIPSgreater thanAPS,greater than
GRD11).
The 33 independent studies reported primary outcome
dataatavarietyofdifferent follow-uptimepoints,withanover-
all sample size of up to 4227participants (Figure 3 andTable).
There wasmeta-analytical evidence of higher risk of psycho-
sis in the BLIPS greater than APS, greater than GRD after 24
months of follow-up, but this effectwas not evident at 6 or 12
months. Across the BLIPS and APS subgroups, the psychosis
risk peaked at 24 months and then plateaued. There was no
meta-analytical evidence that the GRD subgroup had higher
risk of psychosis than the CHR− subgroup at any time point.
SensitivityAnalyses, PublicationBiases, andMeta-regressions
Meta-regressions that investigated year of publication, mean
age of subgroup, proportion of females in each UHR sub-
group, baseline functional level in each subgroup, durationof
untreated attenuated psychotic symptoms, exposure to anti-
psychotics frombaseline to follow-up, psychometricUHRcri-
teria, diagnostic criteria used to assess transition to psycho-
sisat follow-up,andqualityassessmentareappended ineTable
3 in the Supplement. There was a significant effect for publi-
cation year on risk of psychosis onset at 24 months, with the
most recent studies reportinga lower risk than theoldest stud-
ies (eFigure 2A in the Supplement). Ahigher proportionof an-
tipsychotic agent exposure was associated with an increased
risk of psychosis at 36 months (eFigure 2B in the Supple-
ment). All the othermeta-regressions didnot produce signifi-
cant effects.
Sensitivity analyses (results available from the authors on
request) confirmed the robustness of the results at all time
points.Removalofanoutlier identifiedat 12,24,or36months33
did not alter themain findings of significant between-groups
heterogeneity (P < .001). There was no evidence of publica-
tionbiasesas indicatedbyvisual inspectionsof the funnelplots
and by the Egger test for small study effects (eFigure 3A-E in
the Supplement).
Figure 2. Risk of Psychosis Over Time in the Attenuated Psychotic
Symptoms (APS) and Genetic Risk and Deterioration Syndrome (GRD)
vs APS-Alone Groups
0 0.37.03
Study Effect Size (95% CI)
APS and GRD at 6 mo
Subtotal (I2 = 32.26%, P = .11)
APS alone at 6 mo
Subtotal (I2 = 64.51%, P < .001)
0.09 (0.03-0.17)
0.10 (0.07-0.13)
APS and GRD at 12 mo
Subtotal (I2 = 42.10%, P = .03)
APS alone at 12 mo
Subtotal (I2 = 65.92%, P < .001)
0.17 (0.09-0.26)
0.15 (0.12-0.18)
APS and GRD at 24 mo
Subtotal (I2 = 43.32%, P = .03)
APS alone at 24 mo
Subtotal (I2 = 80.01%, P < .001)
0.17 (0.10-0.26)
0.19 (0.15-0.23)
APS and GRD at 36 mo
Subtotal (I2 = 41.77%, P = .09)
APS alone at 36 mo
Subtotal (I2 = 68.94%, P < .001)
0.26 (0.16-0.37)
0.20 (0.16-0.24)
APS and GRD at 48 mo
Subtotal (I2 = 0.00%, P = .43)
APS alone at 48 mo
Subtotal (I2 = 73.54%, P < .001)
0.28 (0.19-0.37)
0.24 (0.17-0.32)
Test for between-group heterogeneity (P > .05 at all time points).
Figure 3. Meta-analytical Stratification of Ultra–High-Risk Individuals
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Secondary Outcomes
The secondary analyses (UHR alone vs BS alone vs UHR and
BS) revealed that, comparedwith theUHRcriteria alone, there
was a higher psychosis risk in the UHR and BS subgroup at 36
months and in theUHRandBS, andBS-alone subgroups at 48
months (eFigure 4 and eTable 4 in the Supplement). How-
ever, these results should be considered exploratory because
there were only very few individual studies included.
Discussion
The current study provided, to our knowledge, the first ro-
bust meta-analytical support for the existence of heteroge-
neous subgroups within the CHR samples. Most of the UHR
individualswere includedat intakebecauseofAPS (85%),with
BLIPS (10%) and GRD (5%) less frequent (eDiscussion 1 in the
Supplement). The meta-analysis indicated that these sub-
groups differed according to the level of risk, with BLIPS hav-
ing a higher transition risk than APS, andAPS having a higher
transition than GRD. Therewas no evidence of enhanced risk
in the GRD subgroup compared with the CHR− subgroup.
We found no evidence supporting additive risk for
comorbid APS and GRD, operationalized as independent
constructs in the psychometric interviews, compared with
APS alone (Figure 2), suggesting that it is the presence of APS
that increases psychosis risk. We therefore combined these
two subgroups to form a joint APS subgroup for the analyses.
The results supported our main hypothesis: there was sub-
stantial between-group (BLIPS vs APS vs GRD vs CHR−)
meta-analytical heterogeneity across all time points
(Figure 3). Post hoc analyses revealed that this was due to a
significantly higher transition risk in the BLIPS subgroup
compared with the other 2 UHR subgroups (eg, 39% vs 19%
in the APS at 24 months) and with the CHR− subgroup. This
was evident at 24-month follow-up and remained significant
in the longer term. Significant differences may not have
been evident at 6 and 12 months because the proportion of
transitions to psychosis at these time points was smaller
than at 24 months.4
The inclusion of the BLIPS subgroup in the CHR has al-
ways been problematic because its diagnostic significance is
unclear34 as it overlayswith the establishedDSM/ICD catego-
ries of brief psychotic disorders. Indeed, some authors have
acknowledged that “patients whose fully psychotic experi-
ence isof sufficient shortduration tomeetDSMcriteria forbrief
psychotic disorder could potentially meet prodromal
criteria.”35(p 707) Competingavailabilityof concurrenthigh risk
(ie,BLIPSorBrief IntermittentPsychoticSymptoms[BIPS]) and
established psychosis labels of similar diagnostic signifi-
cance (eg, Acute and Transient Psychotic Disorder or Brief
Psychotic Disorder) may be a major source of diagnostic
confusion,36withconsequentuseofarbitrarypsychosis thresh-
olds in the field.37,38Whether theBLIPS should be considered
a feature of a high-risk state or an established psychotic dis-
order has been addressed in a separate study.38 Our meta-
analysis clearly reveals that the BLIP subgroup has a distinc-
tive prognosis (with higher risk of psychosis) compared with
the APS subgroup. Our finding concurs with the distinctive
baseline psychopathological presentation2 and therapeutic
needs39 as external validators of BLIPS as a separate clinical
entity from APS.
This finding has a number of potential implications. For
example, itmaybepossible for futureCHRstudies to limit the
recruitment to the APS subgroup to reduce sample heteroge-
neityacrosssubgroups,40whichmightotherwiseconfoundthe
assessmentofgenetic,demographic,andcognitive featuresand
neurobiologicalmeasures,aswell asclinicaloutcomes.Todate,
Table. Risk of Psychosis Across Ultra–High-Risk Subgroups
Follow-up Time, mo BLIPS/BIPS APS GRD CHR−
Total
Sample
Test for
Between-Group
Heterogeneity
(Q) P Value
6
No. of studies (No. of individuals) 19 (219) 19 (1839) 19 (154) 8 (1021) 65 (3233)
119.32 <.001
Mean (95% CI) 0.10 (0.02-0.20) 0.10 (0.08-0.13 0 (0-0.01) 0 (0-0.02)
12
No. of studies (No. of individuals) 24 (294) 24 (2093) 24 (161) 7 (879) 79 (3472)
145.65 <.001
Mean (95% CI) 0.22 (0.14-0.32) 0.16 (0.13-0.19) 0.01 (0-0.05) 0 (0-0.01)
24
No. of studies (No. of individuals) 22 (285) 22 (2694) 22 (196) 8 (1052) 74 (4227)
124.31 <.001
Mean (95% CI) 0.39 (0.7-0.51) 0.19 (0.15-0.23) 0.03 (0-0.08) 0.01 (0-0.03)
36
No. of studies (No. of individuals) 12 (180) 12 (1533) 12 (122) 7 (863) 43 (2698)
62.13 <.001
Mean (95% CI) 0.38 (0.26-0.49) 0.21 (0.16-0.25) 0.05 (0-0.12) 0.01 (0-0.05)
≥48
No. of studies (No. of individuals) 6 (137) 6 (734) 6 (64) 3 (134) 21 (1069)
32.75 <.001
Mean (95% CI) 0.38 (0.28-0.48) 0.24 (0.21-0.27) 0.08 (0-0.19) 0.04 (0-0.13)
Abbreviations: APS, attenuated psychotic symptoms; BIPS, brief intermittent psychotic symptoms; BLIPS, brief limited intermittent psychotic symptoms;
GRD, genetic risk and deterioration syndrome; CHR−, help-seeking individuals not at clinical high risk for psychosis.
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there have been relatively few attempts to compare the fea-
tures of subgroupswithin CHR samples because this requires
large samples.This issuecanbeaddressed inmulticenter stud-
ies.However, another possibilitywould be to retain theBLIPS
in the CHR paradigm but as a distinct and separate subgroup
to facilitate prediction of persisting psychotic disorders38. In
addition, data from our meta-analysis may be useful for fu-
ture designation of CHR programs. Health care professionals
may be able to inform patients and caregivers about relative
risks at a particular time point given their initial intake crite-
ria. Interventions may thus be tailored to the different sub-
groups according to their prognosis. With our meta-analysis
available, it is also arguable that trainingmanuals andpsycho-
metric assessments for CHR individuals be updated to explic-
itly acknowledge the heterogeneity of risk levels associated
with an initial CHR diagnosis.
Post hoc analyses revealed no statistically significant dif-
ferencesbetween theGRDand theCHR−subgroups (Tableand
Figure3). This finding raises important concerns regarding the
validity of the GRD subgroup as a true clinical high-risk syn-
drome, inparticular given the lackof additivevalue for theAPS
designation (Figure 2) and concurrent lack of epidemiologic
validationof this subgroup (prevalence for theAPS andBLIPS
subgroups, but not GRD, has been reported in the general
population41). Our meta-analysis suggests that the GRD con-
struct may not qualify as a state risk criterion42 in that it was
notassociatedwithan impendingrisk forpsychosis in theshort
term (ie, in the first 4 years). However,we cannot exclude the
possibility thatGRD is associatedwithan increased riskofpsy-
chosis during longer intervals,42 particularly because a re-
cent meta-analysis suggested that the impact of familial risk
was only evident after the age of 20 years,43 which was simi-
lar to the mean age in our GRD subgroup. Interpreting nega-
tive results is complexbecause absenceof evidence is not evi-
dence of absence44 andbecausepost hoc retrospective power
analyses are not recommended.45-47 The meta-analytical es-
timates for the GRD subgroup were based on a small sample
(n < 200) and thus yielded a large CI (Figure 3). On the other
hand, similarwidths of CIs (and similar samples of <200 at 36
and ≥48 months) were observed in the BLIPS subgroup
(Figure 3), for which significant meta-analytical differences
were found. It is alsopossible that thedecrease in function cri-
terion required for theGRDsyndrome is too lowor that the in-
struments used to assess functional deteriorationmay not be
the most suitable. The GRD subgroup is also heterogeneous
itself, including individuals with schizotypal personality dis-
ordersandfunctionaldecline inaddition to familial risk forpsy-
chosis. The risk of psychosis in peoplewith a schizotypal per-
sonality disorder is unclear.42 An earlier study48 in 100 CHR
individuals found that schizotypalpersonalitydisorderwas in-
frequentanddidnotpredict conversion.GRDmaybemoreuse-
ful as a distalmarker. In the long term (eg, after 5 years), state
markers may be traded for trait markers, and thus GRD may
reveal better predictive valueduring longer intervals.42Given
that assessingeachUHRentrycriterion isdemandingandchal-
lenging for clinicians and patients, additional research is ur-
gently required toascertain theactual clinical benefit of evalu-
ating GRD features during CHR psychometric interviews.
We additionally tested, for the first time to our knowl-
edge, the specific effect of several moderators of psychosis
risk across each UHR subgroup (eTable 3 in the Supplement).
Sex, quality of studies, type of UHR criteria, and diagnostic
criteria used to assess transition to psychosis did not affect
the level of risk.We also tested for the first time, to our knowl-
edge, via meta-analytical analyses the potential impact of
duration of untreated attenuated psychotic symptoms before
contact with high-risk services,8,49 finding no effect on risk of
psychosis. Level of functioning at baseline similarly had no
impact on risk, in contrast with data from the longest
follow-up study8 in CHR individuals and a recent meta-
analysis50 addressing functional status in CHR patients. There
was also no effect for age, in contrast with our previous
meta-analysis.7 These negative findings may be secondary to
lower statistical power of meta-regressions and limited vari-
ability of moderators included in the current data set, which
was stratified for different subgroups. However, we did con-
firm the decreasing transition risk in the most recent years
(eFigure 2A in the Supplement), as previously described in
original studies51,52 and meta-analytical investigations.7,53 We
also found that increased exposure to antipsychotic treat-
ments was associated with a higher risk of psychosis (eFigure
2B in the Supplement). Such an effect may be confounded by
an increase of symptoms severity, as previously observed in
naturalistic studies of CHR samples39,54 and in a meta-
analysis of randomized clinical trials.55
Overall, this is the first robustmeta-analysis to indicate that
the CHR state comprises subgroups with heterogeneous lev-
els of psychosis risk. Our meta-analysis overcomes the limi-
tations of a previous pilot attempt56 (eDiscussion 2 in the
Supplement) by following the standard recommendedguide-
lines and involving data from studies across the globe
(Europe,United States, Asia, Africa, andAustralia),withmost
studies providing access to additional data as necessary
(27 authors sent additional meta-analytical data).
However, because of limited statistical power associated
with the small number of BS studies, we were unable to pro-
vide conclusive estimates of psychosis risk in this subgroup.
Because the total number of transitions was limited, wewere
similarly unable to differentiate the risk of transition toward
schizophrenia spectrum or affective psychotic disorders.57
We were also unable to test additional moderators potentially
addressing the observed heterogeneity, such as treatments
other than antipsychotics, ethnicity,58 substance abuse,59
and comorbid affective disorders,53,60 because these factors
had not been assessed in the original studies or were
infrequent.
Conclusions
There is meta-analytical evidence of heterogeneous levels of
risk of psychosis in CHR samples. The risk in the BLIPS sub-
group is higher than in the APS subgroup. The GRD subgroup
is rare and not associatedwith an increased risk of psychosis.
Authorsof futureCHRstudies areadvised to stratify their find-
ings across these different subgroups.
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